Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: An immunohistochemical study

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2848-2853

  Baekelandt, Mark ^a   Holm, Ruth ^a   Tropé, Claes G ^a   Nesland, Jahn M ^a   Kristensen, Gunnar B ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; ENZYME REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032723348     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. 1 cyclins. Cell, 73: 1059-1065, 1993.
2. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
3. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
4. 1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.
5. Harper, J. W., Elledge, S. J., Keyomarsi, K., Dynlacht, B., Tsai, L-H., Zhang, P., Dobrowolski, S., Bai, C., Connell-Crowley, L., Swindell, E., Fox, P., and Wei, N. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell, 6: 387-400, 1995.
6. Waga, S., Hannon, G. J., Beach, D., and Stillman, B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.), 369: 574-578, 1994.
7. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
8. 1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
9. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
10. Elbendary, A., Berchuck, A., Davis, P., Havrilesky, L., Bast, R. C., Iglehart, D., and Marks, J. R. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ., 5: 1301-1307, 1994.
11. Wan, M., Cofer, K. F., and Dubeau, L. WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Br. J. Cancer, 73: 1398-1400, 1996.
12. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.
13. Polyak, K., Lee, M-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massagué, J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
14. Toyoshima, H., and Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
15. Luo, Y., Marx, S. O., Kiyokawa, H., Koff, A., Massagué, J., and Marks, A. Rapamycin resistance tied to defective regulation of p21Kip1. Mol. Cell. Biol., 16: 6744-6751, 1996.
16. Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., and Nakayama, K. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.
17. Kiyokawa, H., Kineman, R. D., Manova-Todorova, K. O., Soares, V. C., Hoffman, E. S., Ono, M., Khanam, D., Hayday, A. C., Frohman, L. A., and Koff, A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p21Kip1. Cell, 85: 721-732, 1996.
18. Katayose, Y., Kim, M., Rakkar, A. N. S., Li, Z., Cowan, K. H., and Seth, P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res., 57: 5441-5445, 1997.
19. Kawamata, N., Morosetti, R., Miller, C. W., Park, D., Spirin, K. S., Nakamaki, T., Takeuchi S., Hatta, Y., Simpson, J., Wilczynski, S., Yiul Lee, Y., Bartrarn, C. R., and Koeffler, H. P. Molecular analysis of the cyclin-dependent kinase inhibitor p27/Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.
20. Pagano, M., Tam, S. W., Theodoras A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
21. Kristensen, G. B., and Tropé, C. G. Epithelial ovarian cancer. Lancet, 349: 113-117, 1997.
22. Makar, A. P., Baekelandt, M., Trope, C. G., and Kristensen, G. B. The prognostic significance of residual disease, FIGO substage, tumor histology and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol., 56: 175-180, 1995.
23. Kip1 in malignant melanoma. Am. J. Pathol., 153: 305-312, 1998.
24. Kaplan, E. L., and Meier, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Soc., 53: 457-481, 1958.
25. Cox, D. R. Regression models and life tables (with discussion). J. R. Stat. Soc. London B, 34: 187-209, 1972.
26. Baekelandt, M., Kristensen, G. B., Nesland, J. M., Tropé, C. G., and Holm, R. Clinical significance of apoptosis-related factors p53, Mdm2 and Bcl-2 in advanced ovarian cancer. J. Clin. Oncol., 17: 2061-2068, 1999.
27. waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int. J. Gynecol. Pathol., 16: 149-155, 1997.
28. WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int. J. Cancer, 63: 611-615, 1995.
29. Lukas, J., Groshen, S., Saffari, B., Niu, N., Reles, A., Wen, W-H., Felix, J., Jones, L. A., Hall, F. L., and Press, M. F. WAF1/CIP1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am. J. Pathol., 150: 167-175, 1997.
30. WAF1/CIP1 in human brain tumors. Oncogene, 11: 2021-2028, 1995.
31. waf1/cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. Am. J. Pathol., 151: 461-470, 1997.
32. WAF1/CIP1 expression on tumor progression in bladder cancer. J. Natl. Cancer Inst., 90: 1072-1079, 1998.
33. WAF1/CIP1 in pancreatic cancer. Br. J. Cancer, 76: 299-305, 1997.
34. WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin. Cancer Res., 4: 2615-2623, 1998.
35. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer, 74: 208-215, 1996.
36. WAF1/CIP1 in malignant melanoma. Am. J. Pathol., 149: 1813-1822, 1996.
37. Ito, Y., Kobayashi, T., Takeda, T., Komoike, Y., Wakasugi, E., Tamaki, Y., Tsujimoto, M., Matsuura, N., and Monden, M. Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. Br. J. Cancer, 74: 1269-1274, 1996.
38. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Milburn Jessup, J., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
39. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M, Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
40. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.
41. KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am. J. Pathol., 154: 119-125, 1999.
42. Wang, J., and Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.
43. Zhang, W., Kornblau, S. M., Kobayashi, T., Gambel, A., Calxton, D., and Deisseroth, A. B. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res., 1: 1051-1057, 1995.
44. St. Croix, B., Flørenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., and Kerbel, R. S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
45. KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int. J. Cancer, 77: 796-802, 1998.